Table. 1.
Proteomics pairwise analysis of digested pellet deposits from acute COVID-19 and Long COVID/PASC vs fully digested samples from controls and Type 2 Diabetes
| Digested pellet deposits (microclots) from acute COVID-19 samples vs digested plasma from Control samples | ||
|---|---|---|
| These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested pellet deposits from COVID-19 samples. These proteins were concentrated inside the digested pellet deposits |
| Protein name | Fold change | p-value |
|---|---|---|
| von Willebrand Factor | 4.5 | 0.02 |
| Complement component C4b | 4.2 | 0.05 |
| C-reactive protein | 18.7 | 0.003 |
| Digested pellet deposits from Long COVID/PASC microclots samples vs digested plasma from Control samples | ||
|---|---|---|
| These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested pellet deposits from Long COVID/PASC samples. These proteins were concentrated inside the digested pellet deposits | ||
| Coagulation factor XIII A chain | 6.9 | 0.001 |
| Plasminogen | 3 | 0.001 |
| Fibrinogen alpha chain | 4.1 | 0.0001 |
| α2 antiplasmin (α2AP) | 7.98 | 0.0002 |
| von Willebrand Factor | 10.2 | 0.001 |
| C-reactive protein | 11.2 | 0.007 |
| Serum Amyloid A (SAA4) | 17.5 | 0.01 |
| Complement component C7 | 20 | 0.0002 |
| Digested pellet deposits from Long COVID/PASC microclots samples vs digested pellet deposits (microclots) from acute COVID-19 samples | ||
|---|---|---|
| These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested pellet deposits from Long COVID/PASC samples. These proteins were concentrated inside the digested pellet deposits | ||
| Plasminogen | 2.3 | 0.0007 |
| Fibrinogen β chain | 2.8 | 0.0007 |
| Coagulation factor XIII B | 2.7 | 0.01 |
| Fibrinogen α chain | 3.1 | 0.0002- |
| Complement component C6 | 7.5 | 0.01 |
| α2 antiplasmin (α2AP) | 9.2 | 0.0003 |
| Complement factor 1 | 25 | 0.0009 |
| Digested plasma from T2DM samples (after 1st trypsinization step) vs Long COVID/PASC digested pellet deposits (microclots) (after 2nd trypsinization step) | ||
|---|---|---|
| These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested plasma from the Long COVID samples | ||
| CytoskeletalKeratin, type I | 24.7 | 0.01 |
| Cytoskeletal Keratin, type II | 14 | 0.02 |
| C1q subcomponent subunit B | 1 | 0.03 |
| Digested plasma from control plasma samples vs digested plasma samples from T2DM samples (both plasma sample analysed after 1st trypsinization step) | ||
|---|---|---|
| These proteins are present in both sample types; and a fold change value more than 1 = the protein that more prevalent inside the digested plasma from the diabetes samples | ||
| Complement C1r subcomponent-like protein | 1.5 | 0.04 |
| SAA1 | 2.5 | 0.03 |
All sample types underwent a two-step trypsinization process. Controls vs acute COVID-19; Controls vs Long COVID/PASC; acute COVID-19 vs Long COVID/PASC. The proteins showed here are in both sample types; and value more than 1 = the protein more prevalent in a specific digested pellet deposit. We also compared fold changes between digested plasma (after 1st trypsinisation step) of samples from controls and Type 2 Diabetes Mellitus (T2DM) and between samples from T2DM and Long COVID/PASC (supernatant after 1st trypsinization step only)